Thymosin beta-4
- Generic Name
- Thymosin beta-4
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 77642-24-1
- Unique Ingredient Identifier
- 549LM7U24W
- Background
Thymosin Beta 4 has been investigated for the treatment of STEMI, Dry Eye, Diabetes, Pressure Ulcers, and Dry Eye Syndrome, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- University Of Perugia
- Target Recruit Count
- 9
- Registration Number
- NCT00580450
- Locations
- 🇮🇹
Hematology Section, University of Perugia, Perugia, Italy
Study of Thymosin Beta 4 in Patients With Pressure Ulcers
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2010-02-01
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00382174
- Locations
- 🇺🇸
Impact Clinical Trials, Beverly Hills, California, United States
🇺🇸Hines VAMC, Hines, Illinois, United States
🇺🇸Institute for Advanced Wound Care, Montgomery, Alabama, United States
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00311766
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath